The Role of Tacrolimus in Inflammatory Bowel Disease: A Systematic Review

González-Lama, Yago; Gisbert, Javier P.; Maté, José

doi:10.1007/s10620-006-9209-y

Cited by 36 publications

(21 citation statements)

References 39 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cyclosporine and tacrolimus have also been used as a bridge to thiopurines for refractory UC, particularly in patients who have failed to respond to intravenous corticosteroids. 10,11 …”

Section: Inflammatory Bowel Disease: Overview and Treatment Optionsmentioning

confidence: 99%

Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data

Bewtra

2013

Patient

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), consisting of both Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the intestinal tract. As there is no cure for either CD or UC, these patients face numerous treatment decisions regarding their disease. The aims of this review are to evaluate literature regarding quantitative studies of patient preferences in therapy for IBD with a focus on the emerging technique of stated preference and its application in IBD. Numerous simple survey-based studies have been performed evaluating IBD patients’ preferences for medication frequency, mode of delivery, potential adverse events etc., as well as variations in these preferences. These studies are limited, however, as they are purely descriptive in nature with limited quantitative information on the relative value of treatment alternatives. Time trade-off and standard gamble studies have also been utilized to quantify patient utility for various treatment options or outcomes. However, these types of studies suffer from inaccurate assumptions regarding patient choice behavior. Stated preference is an emerging robust methodology increasingly utilized in health care that can determine the relative utility for a therapy option as well as its specific attributes (such as efficacy or adverse side effects). Stated preference techniques have begun to be applied in IBD and offer an innovative way of examining the numerous therapy options these patients and their providers face.

show abstract

“…Cyclosporine and tacrolimus have also been used as a bridge to thiopurines for refractory UC, particularly in patients who have failed to respond to intravenous corticosteroids. 10,11 …”

Section: Inflammatory Bowel Disease: Overview and Treatment Optionsmentioning

confidence: 99%

Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data

Bewtra

2013

Patient

View full text Add to dashboard Cite

show abstract

“…More recently, tacrolimus has also been successfully applied for the treatment of rheumatoid arthritis [4]. Furthermore, it has been reported that tacrolimus is effective for various other autoimmune diseases, inflammatory bowel disease, myasthenia gravis [5][6][7][8], and lupus nephritis [9,10]. In Japan, a placebo-controlled clinical trial of tacrolimus for lupus nephritis was performed to investigate the efficacy and safety of this agent.…”

Section: Introductionmentioning

confidence: 99%

Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study

et al. 2009

View full text Add to dashboard Cite

We conducted a pilot study to investigate whether tacrolimus was effective for treating patients with systemic lupus erythematosus (SLE) without renal involvement. Ten SLE patients with symptoms such as arthritis and erythema, but no active nephritis, were treated with tacrolimus. They included 8 women and 2 men aged from 24 to 62 years [mean +/- standard deviation (SD): 42.1 +/- 11.3 years]. Tacrolimus was administered at doses of 1-3 mg daily, and efficacy was assessed from the SLE Disease Activity Index (SLEDAI) after 1 year. Two patients ceased treatment due to adverse reactions (after 4 days for chest pain and 7 months for recurrent infections). The other 8 patients completed 1 year of treatment, and significant improvement of disease activity was observed in 6 of them. The mean (+/-SD) SLEDAI showed a significant decrease after 1 year of tacrolimus therapy, from 6.8 +/- 3.1 to 3.4 +/- 0.9; p < 0.05 by Student's paired t test. The mean (+/-SD) dose of prednisolone also decreased significantly, from 16.8 +/- 8.6 to 9.3 +/- 4.6 mg/day; p < 0.05. Although a prospective controlled study will be necessary to confirm, tacrolimus might be a treatment option for active SLE without renal involvement.

show abstract

“…Ciclosporin and tacrolimus (FK506) are different types of molecules that act via a similar mechanism of calcineurin inhibition. They are both effective in patients with UC intolerant of or resistant to conventional immunosuppressants including azathioprine and MP 74–78 …”

Section: Other Anti‐inflammatory Chemical Entitites Evaluated In Ucmentioning

confidence: 99%

Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis

Kamm

2008

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Treatment options for ulcerative colitis (UC) are expanding with the development of novel drug formulations and dosing regimens and new chemical entities. Although the goals of medical therapy for UC remain unchanged, that is to induce and to maintain remission, focus has also centred on improving patient compliance, modifying the natural course of disease and healing the mucosa. Aim To examine novel formulations, new chemical entities and novel therapeutic approaches to the management of UC. Methods Searches for all studies related to UC treatment in Medline and abstracts from major national and international meetings published in the last 10 years. Results 5‐Aminosalicylic acids (5‐ASA) remain the standard first‐line treatment for patients with mild to moderately active UC. New formulations with altered delivery, and new dosing regimens have demonstrated possible improvements in efficacy compared with historically available preparations and dosing patterns. Once‐daily dosing, micropellet formulations, and high‐dose tablets offer enhanced efficacy and improved compliance. 5‐ASA is now recognized as a ligand for peroxisome proliferator‐activated receptor‐γ (PPAR‐γ) and it has a role as a chemo‐preventive agent in long‐standing UC. New colonic release corticosteroid formulations help to limit systemic toxicity; turmeric, tacrolimus and infliximab have shown promising results. New anti‐inflammatory targeted therapies include an anti‐CD3 antibody, selective integrin blockers, anti‐IL‐2 antibody and PPAR‐γ agonists. Conclusion The evolution of novel oral 5‐ASA formulations and dosage regimens, and recent development of new molecules have expanded the therapeutic armamentarium of UC.

show abstract

The Role of Tacrolimus in Inflammatory Bowel Disease: A Systematic Review

Cited by 36 publications

References 39 publications

Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data

Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data

Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study

Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis

Contact Info

Product

Resources

About